| Today’s Big NewsJul 8, 2025 |
| By Gabrielle Masson Taiho Pharmaceutical’s investigational treatment for Duchenne muscular dystrophy (DMD) has failed to impact the time it takes patients to rise from the floor over 52 weeks, missing the phase 3 study’s main goal. |
|
|
|
By James Waldron Many of Concentra’s targets are biotechs that have found themselves in tough times, and Cargo certainly fits the bill. |
By Gabrielle Masson CSL is consolidating its R&D team in an effort to better position the organization “for long-term success in a rapidly evolving global environment.” |
Sponsored by SAP and Answerthink Leaders discuss how built-in best practices and automation streamline growth for lean life sciences teams |
|
| Is your process truly scalable, efficient and validation-ready?Can your supply chain and manufacturing scale flex as your needs evolve?Do you have the manufacturing capacity to deliver when demand takes off? Speak with Lonza’s experts and get answers that drive smarter decisions today.
|
|
By Nick Paul Taylor Rallybio has swerved away from its Recursion Pharmaceuticals pact, accepting $7.5 million upfront for its share of a preclinical program to extend its cash runway to mid-2027. |
By James Waldron ProKidney’s cell therapy for kidney disease has failed to demonstrate a clinically significant preservation of kidney function in one part of a phase 2 study. |
By Kevin Dunleavy Novartis and a Swiss nonprofit have made history, scoring the world’s first approval for a medicine to treat babies who are infected with malaria. The nod is for a new formulation of Coartem, which is also known commercially in come countries as Riamet. |
By Darren Incorvaia Months after announcing an M&A deal with AstraZeneca, EsoBiotec has released the first small slice of data on the cell therapy asset that attracted the Big Pharma’s attention. Four patients with multiple myeloma who received the Belgian biotech’s in vivo T-cell editing therapy all responded to treatment, with the cancer of two patients resolving completely. |
By James Waldron Basilea Pharmaceutica has accessed the next tranche of U.S. government funding required to continue developing its pipeline of new antifungals. |
Fierce podcastsDon’t miss an episode |
| | In this episode of "The Top Line," Teva CEO Richard Francis shares progress on the company’s “Pivot to Growth” strategy and what lies ahead. |
|
|---|
|
|
|
Thursday, July 22, 2025 | 10am ET / 7am PT Join us to take an exciting look at the forefront of REMS transformation. Learn how leading technology, integrated strategies and operational excellence are redefining what’s possible. Gain the insights you need to reduce complexity, enhance compliance and deliver more value across the REMS lifecycle. Register now.
|
|
| WhitepaperThis white paper outlines how we apply industry-backed practices and proprietary technologies to proactively safeguard sterility and performance. Sponsored by: Lonza |
| WhitepaperPresented by Blue Matter, strategic consultants in the life sciences Sponsored by Blue Matter Consulting |
| Executive SummaryBiotech innovation doesn’t slow down—and neither should your lab partner. This brief outlines how early scientific engagement, operational transparency, and integrated global lab services help reduce risk, stay on schedule, and deliver results. Whether you're navigating your first trial or scaling a growing pipeline, see how a purpose-built lab model can help you move smarter and faster. Sponsored by: IQVIA Laboratories |
| |
|
